GlassScriptPhysician profile
Dixon Courson Cunningham
NPI 1487647582
$7,283.38
in general payments reported to CMS, 2019-2025
47 companies · $2,502 in 2025
The $2,502 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,482 · 2020: $165 · 2021: $325 · 2022: $336 · 2023: $1,151 · 2024: $1,322 · 2025: $2,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,584 · Consulting Fee: $300 · Education: $91.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,584.42 |
| Consulting Fee | $300.00 |
| Education | $91.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $753.89 | 2019-2025 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $661.22 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $580.44 | 2019-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $423.59 | 2020-2025 | Botox, Duopa, Ubrelvy |
| Neurocrine Biosciences, INC. | $418.78 | 2023-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $412.31 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $269.19 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Amgen INC. | $265.22 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $264.86 | 2019-2025 | Ultomiris |
| Ucb, INC. | $260.14 | 2019-2025 | Rystiggo, Briviact |
| Acadia Pharmaceuticals INC | $221.86 | 2019-2025 | Nuplazid |
| Eisai INC. | $213.82 | 2019-2025 | |
| Genzyme Corporation | $194.61 | 2019-2025 | |
| Argenx US, INC. | $185.83 | 2023-2025 | Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $160.72 | 2024-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dixon Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.